Une vision stratégique de l'actualité scientifique et technologique du secteur des biotechnologies.

Billets par Aline Aurias

Figures – Biotechnologies & Health in Japan

Japan Gross Domestic Product 2016 was about $4.9 trillions (7.97 % of the world economy). –Japan has been ranked 16th by the Global Innovation Index 2016: • 9th for the proportion of researchers in general population: 5.4 for 1.000 inhabitants • 15th for academia/industry cooperation • 3rd for its R&D intensity : 3.59% of its […]

The biotechnology sector in Japan

With a tradition of fermentation and a strong dependence on imports of food, oil and industrial feedstock, Japan became interested very early on in the potential that biotechnology offered. As early as the 1970s, the Japanese Ministry of International Trade and Industry stated its intent to place the development of life sciences and biotechnology at […]

CELLforCURE, a feedback on Japan

CELLforCURE is a pharmaceutical company specialized in the industrial production of cell and gene therapy medicines. Founded in 2010, it operates since 2013 Europe’s leading industrial platform in terms of capacity. CELLforCURE has operated as a CDMO with several Japanese companies since its creation. Interview with Sébastien Renouf, Director of Pharmaceutical Affairs and Deputy Managing […]

Japanese Life Sciences research and innovation ecosystem

Not unlike France, Japan is struggling to value its academic research, despite its high quality. While its strong industrial research is still reluctant to open up to external influences, the public and private sectors are well aware of the importance of developing a more collaborative research practice.

AMED, for a better allocation of research ressources

AMED, the Japan Agency for Medical Research and Development, has been created in April 2015 to provide a unified funding allocation for medical research expenses which were previously scattered between MEXT, MHLW and METI. This unifying action aims at optimizing resources distribution to establish and maintain coherent research environments throughout Japan.

Portraits of Japanese start-ups

Cyclodextrin based drug development and health food Cyding was born in April 2016. This pre-seed start-up, originated from Kumamoto University (Kyushu), is building off studies on cyclodextrin to enhance the solubility and bioavailability of hydrophobic compounds. The company develops drugs and drug delivery carriers for oncology and gene therapy, and wishes to extend its knowhow […]

Japanese clusters, a broad concept

In Japan, the definition of cluster is not as restricted as in France or Europe. One can find some cluster organisation that closely match their Western counterparts, where an independent institution promotes and supports cooperation between companies, R & D centers and universities within the same region and in their international activities.

Masayo Takahashi, regenerative medicine pioneer

Researcher and clinician at RIKEN Leader of the Retinal Regeneration Laboratory What triggered the shutdown of your first human trial, launched in 2013? In November 2014, a regulatory change required that any clinical study using stem cells be led by a medical institution. RIKEN being a research institute, our trial of age-related macular degeneration treatment […]

HAL reduces the burden on caregivers

The company Cyberdine is a pioneer in the field of cybernetics. Set up in June 2004 by Yoshiyuki Sankai (University of Tsukuba), it has created HAL an exoskeleton for people with reduced mobility or workers subjected to severe physical constraints. www.cyberdyne.jp/english

Kobe, a cluster at the forefront of Japanese medical R & D

Presented by all the players of Japanese innovation as their major cluster in life sciences, the biomedical cluster of Kobe was developed in the ruins of an earthquake. Today, it is pursuing a coherent vision, unchanged for 30 years and which has proved successful. Initially, a revitalization project Kobe is historically a zone of heavy […]

Dernière Lettre parue

Cliquez sur l'image pour accéder à la lecture via Calaméo (accès réservé aux abonnés)
Cliquez sur l'image pour accéder à la lecture via Calaméo (accès réservé aux abonnés)


(abonnement aux éditions de la Lettre et accès intégral au site)

Abonnez-vous à notre newsletter gratuite

InnovIn Med